A series of aroxyacetamides and aroxyethylamines were prepared and evaluated for anticonvulsant activity in the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole seizure threshold (ScMet) assays and for neurotoxicity (TOX). Most of them exhibited anticonvulsant activity in the MES screen (mice, i.p.) in the doses up to 300 mg/kg b.w. The most active compound was XVI, which given in the dose 100 mg/kg b.w. produced 100% anticonvulsant protection after 0.5 h without neurotoxicity. The most promising compound in the VIa phase (rats, p.o.) was VIII, which produced higher anticonvulsant protection (to 75% at 0.5 h).